CONCORDBIO · Healthcare · Biotechnology
Composite scorecard: 56/100 — Quality 95 · Valuation 21 · Growth 70 · Momentum 0
| Share price | ₹1,335.00 |
| Market cap | ₹12,769 Cr |
| P/E ratio | 41.0 |
| P/B ratio | 7.0 |
| ROE | 21.8% |
| ROCE | 26.8% |
| Dividend yield | 0.88% |
| Book value | ₹173.32 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,055 Cr | ₹259 Cr | 35.0% |
| 2025 | ₹1,200 Cr | ₹372 Cr | 42.0% |
| 2024 | ₹1,017 Cr | ₹308 Cr | 42.0% |
| 2023 | ₹853 Cr | ₹240 Cr | 40.0% |
| 2022 | ₹713 Cr | ₹175 Cr | 38.0% |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinom